• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lilly and Ypsomed team up on automated insulin delivery

November 19, 2020 By Brian Buntz

Eli LillyEli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are teaming up to create an automated insulin delivery system. Lilly would commercialize the device, which would incorporate an insulin pump from Ypsomed.

Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen.

Lilly plans on commercializing a version of this pump in tandem with a continuous glucose monitor to automate insulin delivery in the U.S. and Europe. The pump would use Lilly’s cartridges containing rapid-acting insulins.

While some companies refer to such automated technology as an “artificial pancreas,” Lilly opts for the phrase “automated insulin delivery system” to describe the connected devices that adjust a person’s insulin dosing based on continuous analysis and their glucose readings.

“Our goal is to simplify diabetes management and develop the best possible solutions by pairing our deep expertise in insulin with other companies,” said a Lilly spokesperson. “We believe that the flexibility and convenience of Ypsomed’s insulin pump will help improve outcomes in people with diabetes and our collaboration with Ypsomed also focuses on Ypsomed’s automated insulin delivery technology.”

In particular, Lilly anticipates that the technology can help people with diabetes optimize blood sugar control, time in range, A1C levels and other variables. “Our collaboration with Ypsomed highlights our continued progress toward a holistic solution for diabetes management,” the Lilly spokesperson added.

Ypsomed signed a similar deal with Novo Nordisk (NYSE:NVO) in 2016 to use the YpsoPump with Novo Nordisk’s NovoRapid PumpCart.

Ypsomed hopes to win FDA permission to use the YpsoPump for automated insulin delivery in 2022. Lilly would have exclusive rights to commercialize the pump in the U.S.

“Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms,” said Simon Michel, Ypsomed CEO, in a statement.

 

Filed Under: Diabetes, Drug-Device Combinations Tagged With: Eli Lilly & Co., Novo Nordisk, Ypsomed, YpsoPump

IN CASE YOU MISSED IT

  • BriaCell Therapeutics closes $25M offering
  • ICU Medical dips despite Street-beating Q4
  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS